Triple‐negative breast carcinoma (TNBC), defined by the immunohistochemical absence of estrogen receptor, progesterone receptor, and HER2/neu expression, represents the most therapeutically challenging breast cancer subtype with aggressive metastatic potential. This evidence concerns the gene ERBB2 and breast cancer.